Sodium–glucose cotransporter-2 inhibitors in diabetes and inflammatory skin diseases
- 29 May 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (3) , 467-468
Abstract
Treatment with sodium–glucose cotransporter-2 inhibitors (SGLT2i) is associated with a decreased risk of new-onset inflammatory skin diseases, including vitiligo, acne vulgaris, rosacea and urticaria in patients with diabetes. Prospective studies and clinical trials are warranted to validate the safety and efficacy of SGLT2i in patients with diabetes and concomitant inflammatory skin diseases.Keywords
This publication has 7 references indexed in Scilit:
- Metformin-Induced Acute Urticaria Mimicking Chronic Spontaneous UrticariaDermatitis®, 2024
- Effects of sodium-glucose cotransporter-2 inhibitors on inflammatory skin diseases in patients with type 2 diabetesJournal of the American Academy of Dermatology, 2024
- Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunityCell Metabolism, 2023
- Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidneyEuropean Journal of Pharmacology, 2023
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 DiabetesJAMA Cardiology, 2021
- Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic reviewLife Sciences, 2020
- Dietary glycemic factors, insulin resistance, and adiponectin levels in acne vulgarisJournal of the American Academy of Dermatology, 2016